GSK forays into oncology in India with Jemperli and Zejula
The company is bringing precision therapies for gynaecological cancers
The company is bringing precision therapies for gynaecological cancers
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
The company has improved access to quality healthcare for seniors across both urban and rural areas
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
NATCO holds the first-to-file status for this product and will have 180-day generic drug exclusivity
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
The accelerated approval is supported by results from part 1 of the ESSENCE trial
Subscribe To Our Newsletter & Stay Updated